Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Tardif, JC; Karwatowska-Prokopczuk, E; St Amour, E; Ballantyne, CM; Shapiro, MD; Moriarty, PM; Baum, SJ; Hurh, E; Bartlett, VJ; Kingsbury, J; Figueroa, AL; Alexander, VJ; Tami, J; Witztum, JL; Geary, RS; O'Dea, LS; Tsimikas, S; Gaudet, D

Tardif, JC (通讯作者)，Montreal Heart Inst, Jean Claude Tardif MD Res Ctr, 5000 Belanger St, Montreal, PQ H1T 1C8, Canada.;Tsimikas, S (通讯作者)，Ionis Pharmaceut Inc, 2855 Gazelle Court, Carlsbad, CA 92010 USA.;Tsimikas, S (通讯作者)，Univ Calif San Diego, Div Cardiovasc Med, 9500 Gilman Dr,BSB1080, La Jolla, CA 92093 USA.

EUROPEAN HEART JOURNAL, 2022; 43 (14): 1401

Abstract

Aims Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosam......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索